Breast cancer is the most common and the leading cause of mortality in women worldwide. There is a dire necessity of the identification of novel molecules useful in diagnosis and prognosis. In this work we determined the differentially expression profiles of four breast cancer cell lines compared to a control cell line. We identified 1020 polypeptides labelled with iTRAQ with more than 95% in confidence. We analysed the common proteins in all breast cancer cell lines through IPA software (IPA core and Biomarkers). In addition, we selected the specific overexpressed and subexpressed proteins of the different molecular classes of breast cancer cell lines, and classified them according to protein class and biological process. Data in this article is related to the research article “Determination of the protein expression profiles of breast cancer cell lines by Quantitative Proteomics using iTRAQ Labelling and Tandem Mass Spectrometry” (Calderón-González et al. [1] in press).
Cita bibliográfica / Cita bibliogràfica (ISO 690):BORDES, Mari Carmen, et al. Preparation of feedstocks from nano/submicron-sized TiO 2 particles to obtain photocatalytic coatings by atmospheric plasma spraying. Ceramics International, 2014, vol. 40, no 10, p. 16213-16225.
AbstractAtmospheric plasma spraying (APS) has been proved useful in obtaining TiO 2 coatings with effective photocatalytic activity. However, the influence of feedstock characteristics on photocatalytic activity has hardly been addressed.This study was undertaken to prepare TiO 2 photocatalytic coatings by APS from different feedstocks. The feedstocks were obtained by spray drying suspensions of a nano-and a submicron-sized TiO 2 powder, with different solids contents and/or ratios of the nano-to submicron-sized particles. All the resulting powders were fully 2 characterised to assess their suitability for use in APS processes. Feedstock powders were then deposited on steel coupons by APS using hydrogen or helium as secondary plasma gas. Coating microstructure and phase composition were characterised. Coating photocatalytic activity was determined by measuring the degradation of methylene blue dye in an aqueous solution.Powder characterisation showed that all feedstocks met plasma spray operation requirements with regard to agglomerate size distribution and density, as well as to powder flowability. Optimum agglomerate density was obtained when a well-balanced mixture of nano-and submicron-sized particles was used.All coatings displayed a bimodal microstructure with partially melted agglomerates that retained the initial nano-or submicron-sized structure and composition (anatase phase) of the feedstock, surrounded by a fully melted matrix mainly formed by rutile. As expected, coating porosity as well as the amount of partially melted areas depended strongly on plasma spray conditions and on feedstock characteristics.With regard to photocatalytic activity, a reasonably good fit of a first-order kinetic model to the experimental data was found for all coatings. The kinetic constants obtained displayed higher values than those of a commercial sol-gel coating. The values of these constants were related to feedstock characteristics as well as to plasma spraying conditions on the basis of anatase content. The contribution of other factors to the resulting coating surface is also discussed.
Background: The aim of this phase I trial was to define the maximum tolerated dose (MTD), the dose-limiting toxicity (DLT) and the recommended dose of erlotinib combined with capecitabine and gemcitabine in the treatment of advanced pancreatic cancer (APC). Methods: Gemcitabine was administered intravenously at 1,000 mg/m2/week (days 1, 8 and 15) and oral capecitabine from day 1 to day 21 at 1,660 mg/m2/day. Oral erlotinib was administered daily continuously at escalating doses (28-day cycle). Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively. Pharmacokinetic analysis of the three drugs was performed in the first cycle. Results: Nineteen patients were enrolled. At the MTD (DL4; 125 mg/day erlotinib), 100% of patients developed DLT consisting of grade 4 febrile neutropenia and nonhematological grade 3 events (vomiting, diarrhea, stomatitis, rash). The most common toxicities, regardless of grade, were neutropenia, anemia, rash and diarrhea. Erlotinib systemic exposure was significantly related to the administered dose. Of note, toxicity was significantly associated with elevated systemic exposure of capecitabine anabolites. Conclusion: When combined concurrently with 1,000 mg/m2/week gemcitabine and 1,660 mg/m2/day capecitabine, erlotinib can be administered safely at a daily dose of 100 mg in APC patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.